Werewolf Therapeutics Q4 net loss narrows as expenses fall

Werewolf Therapeutics

27/03/2026 11:10

Overview

US biopharmaceutical firm's Q4 net loss narrowed yr/yr

Operating expenses for Q4 declined compared to prior year

Company initiated process to explore strategic alternatives including sale of assets or merger

Outlook

Werewolf Therapeutics is evaluating strategic alternatives, including sale, merger, or asset transactions

Company does not have a defined timeline for strategic evaluation and cannot assure any outcome

Werewolf expects cash and equivalents to fund operations into the fourth qtr of 2026

Result Drivers

EXPENSE REDUCTIONS - Co attributed lower Q4 net loss to decreased research and development and general and administrative expenses

Company press release: ID:nGNXbfmPjF

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Net Income
-$8.38 mln
Q4 Basic EPS
-$0.17
Q4 Operating Expenses
$9.42 mln
Q4 Operating Income
-$9.42 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Werewolf Therapeutics Inc is $5.50, about 537.2% above its March 26 closing price of $0.86

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)